What happened with VALN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Most of Valneva SE’s revenue comes from IXIARO, which prevents Japanese encephalitis, and DUKORAL, which prevents cholera and certain bacterial diarrhea in some approved markets. Travelers buy these vaccines before visiting regions where the diseases occur, and the U.S. Department of Defense is a major IXIARO customer, buying doses for deploying military personnel. Valneva manufactures the vaccines and sells them through its own commercial teams and distributors. Canada is DUKORAL’s largest market.
These sales help fund development of new vaccines and depend on international travel, customers’ willingness to pay and reliable manufacturing. Valneva also sells the chikungunya vaccine IXCHIQ, but serious adverse-event reports have restricted its use. Its U.S. license was withdrawn after an FDA suspension; it remains available in other approved markets under country-specific warnings and age limits. Valneva also cannot currently use its new Almeida facility to make IXIARO for U.S. distribution because of unresolved FDA compliance issues, although its Manson facility remains licensed.
A separate potential income source is VLA15, its Lyme disease vaccine candidate partnered with Pfizer. Pfizer leads late-stage development and, if the vaccine is approved, will control manufacturing and commercialization. Valneva would be eligible for milestone payments and royalties on sales, making this income dependent on approval and Pfizer’s commercialization decisions.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Valneva’s results hinge on travel-vaccine demand and VLA15’s success; Bavarian Nordic, absent from this list, is a rival to watch because its Vimkunya competes with IXCHIQ.
Valneva depends on Pfizer to co-develop VLA15 and, if approved, manufacture and sell the Lyme disease vaccine, paying Valneva milestones and royalties on sales. Watch Pfizer’s VLA15 trial and approval news: Valneva says failure to meet the pivotal trial’s primary endpoints would force restructuring and cost cuts.
Moderna’s experimental Lyme disease vaccines could compete with VLA15, the vaccine Valneva is developing with Pfizer to earn milestones and sales royalties. Moderna currently earns most of its revenue from COVID-19 vaccine sales; its Phase I/II mRNA-1982 and mRNA-1975 trial progress is the news to watch for Valneva.
Sanofi competes for the travel-clinic buyers Valneva serves by selling travel vaccines against diseases including rabies and typhoid. It no longer owns IMOJEV, the Japanese encephalitis vaccine that competes with Valneva’s vaccine.
GSK serves the same travel clinics and travelers as Valneva, selling them hepatitis vaccines while Valneva sells Japanese encephalitis and cholera vaccines. The overlap is in the buyers, rather than vaccines against the same diseases.
Kamada supplies the KamRAB rabies immunoglobulin Valneva sells in Canada and also buys Valneva products for its own distribution business in Israel. KamRAB is Valneva’s only remaining third-party distribution contract for 2026, making it the product to watch in that revenue line.
Sanofi earningsSNY
Sanofi’s report can show how travel-vaccine demand and competition are shaping up among the clinics and travelers that Sanofi and Valneva both serve.
Look for Sanofi’s travel-vaccine sales and commentary, while separating market demand from a competitor’s performance. Stronger sales could suggest clinics and travelers are supporting demand; if Sanofi’s relevant products are doing better, it may be winning more business from shared buyers, increasing the competitive pressure on Valneva in travel clinics.
Pfizer Inc. earningsPFE
Pfizer leads late-stage development of the Lyme vaccine VLA15 with Valneva, so its report’s program update could affect Valneva’s chance of future milestone and sales-royalty payments.
Watch for any Pfizer update on VLA15’s trial or approval progress and next steps. Continued progress keeps open the possibility of future milestones and royalties for Valneva, but neither the amount nor timing is assured. A setback or delay would weaken that revenue prospect and could leave Valneva needing to contain costs.
Moderna, Inc. earningsMRNA
If Moderna’s report updates its Lyme-vaccine trials, it can show whether VLA15, Valneva’s program with Pfizer, may face a stronger future competitor.
Watch for trial progress in Moderna’s Lyme-vaccine candidates, keeping in mind that they are at an earlier development stage than VLA15. Continued progress would add a potential future rival and make VLA15’s ability to win market share after launch less certain; a stall would reduce the visible competitive threat, but would not prove VLA15 will succeed.
Kamada Ltd earningsKMDA
If Kamada’s report shows a change in KamRAB sales or demand, it can indicate how much support Valneva’s Canadian distribution of the rabies immunoglobulin has.
Look for Kamada’s disclosures on KamRAB sales or demand, and keep them separate from Kamada’s distribution of Valneva products in Israel. Stronger KamRAB demand could support Valneva’s Canadian distribution revenue; weaker demand could reduce the contribution from the only third-party distribution contract Valneva says it has remaining for 2026.
Valneva SE earningsThis company
Valneva’s report will show whether IXIARO and DUKORAL sales continue to support the business, and whether IXCHIQ can add sales without adding more inventory costs amid restrictions and competition.
Read IXIARO and DUKORAL sales alongside IXCHIQ sales and any related cost, inventory-revaluation or write-off pressure. Steady sales from the first two, with IXCHIQ sales rising without costs swelling, would show the established products are supporting revenue as IXCHIQ begins to contribute. If core sales weaken or IXCHIQ’s costs and inventory burden outweigh its sales, the portfolio is still struggling to carry the business.
